Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)

“We focused on steady execution during the first quarter, highlighted by the full enrollment of the navacaprant KOASTAL-2 and -3 studies with more than 400 patients per study. We look forward to the topline readout of these studies this quarter,” said Paul L. Berns, chairman and chief executive officer, Neumora. “Additionally, we reported the Phase 1b study with NMRA-511 demonstrating an unsurpassed clinical effect in Alzheimer’s disease agitation and we remain on track to report data from the MAD expansion cohort in the second half of 2026, with a Phase 2 study anticipated to begin in the first quarter of 2027.”